Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | XPO1 | O14980 | 2/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565119 | 1.00 | CSNK1D (0.36) | CSNK1DMAPTXPO1GSTP1CACNA1D | |
| SCHEMBL1098829 | 0.89 | NPC1 (0.36) | MAPTXPO1GSTP1NPC1RAB9A | |
| SCHEMBL1101121 | 0.88 | ALDH1A1 (0.36) | CSNK1DMAPTMEN1KMT2ALMNA | |
| SCHEMBL825195 | 0.88 | MAPT (0.32) | MAPTGSTP1MEN1KMT2ALMNA | |
| SCHEMBL29823665 | 0.88 | MAPT (0.32) | MAPTGSTP1MEN1KMT2ALMNA | |
| SCHEMBL1100680 | 0.87 | NPC1 (0.37) | MAPTLMNANPC1RAB9A | |
| SCHEMBL1100484 | 0.86 | NPC1 (0.38) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL1100373 | 0.86 | MAPT (0.34) | MAPTMEN1KMT2ALMNANPC1 | |
| SCHEMBL20961133 | 0.85 | MC4R (0.36) | CSNK1DGSTP1CACNA1DPTGS1MC4R | |
| SCHEMBL10020867 | 0.85 | MAPT (0.33) | MAPTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223392-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC (CH) | 2025-07-10 | — | — | US | claimed |
| US-20240254269-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC. (CH) | 2024-08-01 | — | — | US | claimed |
| US-11926689-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2024-03-12 | — | — | US | claimed |
| EP-3303415-B1 | VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF | ALCON INC (CH) | 2022-12-28 | — | — | EP | claimed |
| US-20220380509-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC. (CH) | 2022-12-01 | — | — | US | claimed |
| US-11453736-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2022-09-27 | — | — | US | claimed |
| EP-3743270-B1 | CAST-MOLDING PROCESS FOR PRODUCING UV-ABSORBING CONTACT LENSES | ALCON INC (CH) | 2022-06-08 | — | — | EP | claimed |
| US-11111327-B2 | Cast-molding process for producing UV-absorbing contact lenses | ALCON INC. (CH) | 2021-09-07 | — | — | US | claimed |
| US-20210009743-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC. (CH) | 2021-01-14 | — | — | US | claimed |
| US-10870722-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2020-12-22 | — | — | US | claimed |
| US-20150094393-A1 | METHOD FOR MAKING UV-ABSORBING OPHTHALMIC LENSES | ALCON INC. (CH) | 2015-04-02 | — | — | US | claimed |
| EP-2346840-B1 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | NOVARTIS AG (CH) | 2013-12-25 | — | — | EP | claimed |
| EP-2564245-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | Novartis AG (CH) | 2013-03-06 | — | — | EP | claimed |
| US-8262948-B2 | Intraocular lenses with combinations of UV absorbers and blue light chromophores | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | claimed |
| US-8153703-B2 | UV/visible light absorbers for ophthalmic lens materials | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | claimed |
| WO-2011137142-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | claimed |
| US-20110266505-A1 | INTRAOCULAR LENSES WITH COMBINATIONS OF UV ABSORBERS AND BLUE LIGHT CHROMOPHORES | ALCON INC. (CH) | 2011-11-03 | — | — | US | claimed |
| EP-2346840-A1 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | Alcon, Inc. (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010053917-A1 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | ALCON, INC. (CH) | 2010-05-14 | — | — | WO | claimed |
| US-20100113641-A1 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | ALCON, INC. (CH) | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113641-A1 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS | UACA, CRYZ, CRYAA | CSNK1D 4202/4885MAPT 45/4885XPO1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.